The earnings call highlights strong regulatory progress and clinical achievements, particularly with ProSense's anticipated FDA approval and significant adoption in Europe and Japan. However, these positives are tempered by financial challenges, including decreased revenue, gross profit, and continued net losses, partly due to geopolitical issues.

Company Guidance -

Q3 2025

During the conference call, IceCure Medical provided guidance on several key metrics and anticipated developments. The company remains optimistic about receiving FDA approval for ProSense by the end of 2025, especially following a productive meeting with the FDA concerning their de novo marketing authorization request. They highlighted the potential of ProSense to transform breast cancer care for approximately 46,000 women in the U.S. annually, noting the FDA's request for a post-market study involving 400 patients across 30 sites. Financially, IceCure reported $1.25 million in revenue for the first half of 2025, a decrease from $1.75 million in the same period of 2024, partly due to shipment delays caused by geopolitical conflicts. Their gross profit also fell to $349,000 from $799,000, with a gross margin of 28% versus 46% the previous year. Despite these figures, operating expenses decreased slightly to $7.39 million from $7.68 million, reflecting cost optimization efforts. The company ended the period with $5.38 million in cash and equivalents, excluding $10 million from a recent rights offering. IceCure anticipates that its financial position will support continued progress across regulatory, clinical, and commercial initiatives, with expectations of accelerating growth following the FDA's decision.

Regulatory Progress for ProSense

IceCure concluded a productive meeting with the FDA regarding de novo marketing authorization for ProSense, with optimism for approval before year-end 2025. The FDA requested a post-market study, which has been fully submitted and awaits feedback.

Increased Adoption in Europe

ProSense has seen a positive shift in adoption in Europe for breast cancer cryoablation, driven by ICE3 results and growing clinical evidence. The technology was featured prominently in several high-impact medical forums.

Successful $10 Million Rights Offering

IceCure strengthened its financial position with a $10 million rights offering that was significantly oversubscribed, providing a sufficient cash runway for the anticipated FDA decision.

Strong Clinical Results in Japan

17 years of data from over 600 breast cancer patients in Japan showed a 99% recurrence-free rate with cryoablation, demonstrating significant clinical success.

Icecure Medical (ICCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ICCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 25, 2025	2025 (Q3)	-0.06 / -	-0.078	―	―	―
Aug 13, 2025	2025 (Q2)	-0.06 / -0.06	-0.059	-1.69% (>-0.01)	―
May 28, 2025	2025 (Q1)	-0.08 / -0.06	-0.078	24.36% (+0.02)	―
Mar 27, 2025	2024 (Q4)	-0.07 / -0.08	-0.059	-32.20% (-0.02)	―
Nov 26, 2024	2024 (Q3)	-0.07 / -0.08	-0.088	11.36% (<+0.01)	―
Aug 20, 2024	2024 (Q2)	-0.07 / -0.06	-0.088	32.95% (+0.03)	―
May 28, 2024	2024 (Q1)	- / -	-0.078	―	―
Apr 03, 2024	2023 (Q4)	-0.07 / -0.08	-0.078	0.00% (0.00)	―
Nov 15, 2023	2023 (Q3)	-0.09 / -0.09	-0.108	18.52% (+0.02)	―
Aug 14, 2023	2023 (Q2)	-0.09 / -0.09	-0.118	25.42% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ICCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.82	$0.84	+2.44%
May 28, 2025	$1.11	$1.01	-9.01%
Mar 27, 2025	$1.12	$1.08	-3.57%
Nov 26, 2024	$0.76	$0.77	+1.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does IceCure Medical (ICCM) report earnings?

IceCure Medical (ICCM) is schdueled to report earning on Nov 25, 2025, TBA (Confirmed).

What is IceCure Medical (ICCM) earnings time?

IceCure Medical (ICCM) earnings time is at Nov 25, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ICCM EPS forecast?

ICCM EPS forecast for the fiscal quarter 2025 (Q3) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing